Navigation Links
Halozyme Receives $5.5 Million Payment From Baxter
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced receipt of $5.5 million from Baxter Healthcare Corporation representing the final prepaid product-based payment due under the terms of its HYLENEX licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been booked as deferred revenue.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com.

    Halozyme Contact
    Robert H. Uhl
    Senior Director, Investor Relations
    (858) 704-8264
    ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a Regional Top ... Top 10 Plastic Surgeon Specialists for Nashville, TN – has ... line includes a Hydration Booster, Retexturing Night Crème, and Anti-aging ... a younger, more radiant appearance while protecting them from the ... is why at Dr. J. J. Wendel Plastic Surgery, we ...
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ion ... has been granted patent number 8,789,826 by the U.S. ... a unique specimen carrier support grid design described in ... patent for EXpressLO LLC awarded to founder and President, ... patents extend EXpressLO’s portfolio of intellectual property. The EXpressLO™ ...
(Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Building 'invisible' materials with light 2WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... The Netherlands, June 24 The U.S. Department,of Energy,s ... to enable the sale and delivery of an Avantium ... PNNL to,accelerate its catalyst research for infrastructure compatible biofuels ... by Battelle for the U.S. Department of Energy. The,Laboratory ...
... New Report Calls for a Broad Ethics of Emerging Technologies ... of synthetic biology will allow researchers to create biological parts ... to re-engineer existing organisms to perform novel and beneficial tasks. ... to addressing ethical and social issues is called for, especially ...
... WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the company has reached an agreement with the U.S. ... assessment process (SPA) on an amendment to the design ... lead product candidate targeting castrate resistant prostate cancer (CRPC). ...
Cached Biology Technology:Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA 2Does Synthetic Biology Need Synthesized Ethics? 2Does Synthetic Biology Need Synthesized Ethics? 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5
(Date:7/29/2014)... researchers have developed an easier method to create ... work involved in diagnosing diseases. , DNA linked ... strong partnership that can be used in diagnostic ... which tag proteins with DNA can be ... and visualisation of biological material. The method also ...
(Date:7/29/2014)... There,s some good news for parents of preterm babies ... that by the time they become teenagers, the brains of ... born at term. , A study conducted by the University,s ... as the preterm child experiences no brain injury in early ... as good as their term-born peers. , However, the results ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2
... predicted to occur under climate change scenarios has led many ... of wildfires. But a new study in the May issue ... changes in the types of plants growing in an area ... Philip Higuera of Montana State University and his colleagues ...
... Orleans, LA Sharell Bindom, a student in the ... will be awarded the Mead Johnson Research Award in ... the 2009 Experimental Biology Meeting April 18-22 in New ... is intended to recognize the graduate student, resident, or ...
... do all sorts of work, but a fundamental question has ... "There,s no little man sitting there, putting the protein ... biologist at the USC College of Letters, Arts and Sciences. ... tells them where to go in the cell." In ...
Cached Biology News:Plants could override climate change effects on wildfires 2Autopilot guides proteins in brain 2
... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
... acid synthetic peptide whose sequence corresponds to residues 115-133 of rat ... terminus): V115 - L - P - S - E ... V - P - N - E - V - L ... been added to facilitate conjugation and is not a part of ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: